Aurinia Pharmaceuticals Inc.

NasdaqGM:AUPH Stock Report

Market Cap: US$724.5m

Aurinia Pharmaceuticals Dividend

Dividend criteria checks 0/6

Aurinia Pharmaceuticals does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield2.7%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Earnings per share-US$0.54
Dividend yield forecast in 3Yn/a

Recent dividend updates

No updates

Recent updates

Aurinia Pharma: Cheaper Now, But Buyout Hopes Dashed

Mar 05

Analysts Have Been Trimming Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Price Target After Its Latest Report

Feb 19
Analysts Have Been Trimming Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Price Target After Its Latest Report

Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) 26% Dip In Price Shows Sentiment Is Matching Revenues

Feb 17
Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) 26% Dip In Price Shows Sentiment Is Matching Revenues

Aurinia Pharmaceuticals 2023 Earnings Review: Calling 'Time' In Last Chance Saloon

Feb 15

Aurinia Pharmaceuticals: Sales Growth Would Help Buyout Potential

Jan 28

We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow

Jan 05
We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow

Insufficient Growth At Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Hampers Share Price

Dec 18
Insufficient Growth At Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Hampers Share Price

Aurinia Pharmaceuticals (NASDAQ:AUPH) Is In A Strong Position To Grow Its Business

Sep 14
Aurinia Pharmaceuticals (NASDAQ:AUPH) Is In A Strong Position To Grow Its Business

Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Low P/S No Reason For Excitement

Jun 11
Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Low P/S No Reason For Excitement

Broker Revenue Forecasts For Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Are Surging Higher

May 09
Broker Revenue Forecasts For Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Are Surging Higher

We're Not Worried About Aurinia Pharmaceuticals' (NASDAQ:AUPH) Cash Burn

May 01
We're Not Worried About Aurinia Pharmaceuticals' (NASDAQ:AUPH) Cash Burn

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Analysts Just Trimmed Their Revenue Forecasts By 26%

Nov 04
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Analysts Just Trimmed Their Revenue Forecasts By 26%

Aurinia Pharmaceuticals wins European approval of Lupkynis for lupus

Sep 19

Aurinia Pharmaceuticals: The Right Play Now

Aug 24

Aurinia Pharmaceuticals: Updating My Revenue And Valuation Model

Aug 15

Aurinia Pharma Q2 2022 Earnings Preview

Aug 03

Aurinia lupus nephritis drug recommended in Europe

Jul 22

A Buyout-Driven Pair Trade: Buy Aurinia, Sell Merck (Or Seagen If You Must)

Jul 04

Aurinia: Redemption On Lupkynis Sales And Possible EMA Approval

May 20

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if AUPH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AUPH's dividend payments have been increasing.


Dividend Yield vs Market

Aurinia Pharmaceuticals Dividend Yield vs Market
How does AUPH dividend yield compare to the market?
SegmentDividend Yield
Company (AUPH)n/a
Market Bottom 25% (US)1.5%
Market Top 25% (US)4.6%
Industry Average (Biotechs)2.7%
Analyst forecast in 3 Years (AUPH)n/a

Notable Dividend: Unable to evaluate AUPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AUPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate AUPH's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as AUPH has not reported any payouts.


Discover strong dividend paying companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.